EP2508535 - Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.09.2013 Database last updated on 03.09.2024 | Most recent event Tooltip | 06.09.2013 | Application deemed to be withdrawn | published on 09.10.2013 [2013/41] | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris / FR | [2012/41] | Inventor(s) | 01 /
Faivre, Jamila 5 rue du Général Delestraint 75016 Paris / FR | 02 /
Herve, Julie 8 Résidence Delattre De Tassigny Route des Ponts de Cé 49000 Angers / FR | 03 /
Clerc, Jérôme 6 rue Toullier 75005 Paris / FR | 04 /
Brechot, Christian 35 Boulevard Pasteur 75015 Paris / FR | [2012/41] | Representative(s) | Jacobacci Coralis Harle 32, rue de l'Arcade 75008 Paris / FR | [N/P] |
Former [2012/41] | Coralis Harle 14-16 Rue Ballu 75009 Paris / FR | Application number, filing date | 12174478.3 | 12.09.2007 | [2012/41] | Priority number, date | EP20060300942 | 12.09.2006 Original published format: EP 06300942 | [2012/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2508535 | Date: | 10.10.2012 | Language: | EN | [2012/41] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 12.09.2012 | Classification | IPC: | C07K14/47, C12N15/79, C12N15/63, C12N15/861, A61K48/00, C12Q1/68 | [2012/41] | CPC: |
C12N15/85 (EP,US);
A61P35/00 (EP);
A61P35/02 (EP);
C12N15/113 (EP,US);
A61K48/00 (EP,US);
C12N2310/111 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2012/41] | Title | German: | Nucleinsäure zur Expression eines relevanten Polynucleotids in Säugetierkrebszellen | [2012/41] | English: | Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells | [2012/41] | French: | Acides nucléiques pour l'expression d'un polynucléotide d'intérêt dans des cellules cancéreuses de mammifères | [2012/41] | Examination procedure | 11.04.2013 | Application deemed to be withdrawn, date of legal effect [2013/41] | 21.05.2013 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2013/41] | Parent application(s) Tooltip | EP07803443.6 / EP2069398 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070803443) is 22.06.2010 | Fees paid | Renewal fee | 29.06.2012 | Renewal fee patent year 03 | 29.06.2012 | Renewal fee patent year 04 | 29.06.2012 | Renewal fee patent year 05 | 02.08.2012 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO2005007832 (CELL GENESYS INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.23, l.4 to p.24, l.6; p.32, l.21 to p.34, l.17 and SEQ ID NO: 5 * [Y] 6; | [XY]US2003152553 (LITTLE ANDREW S [US], et al) [X] 1-3,5,7-15 * the whole document, in particular [0061], [0122-0125], Example 3 and SEQ ID NO: 5 * [Y] 6; | [XY]WO0173093 (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular Figure 5; p.37, l.14 to p.39, l.2; Examples 1,5,9, SEQ ID NO: 16, claims 24, 58 * [Y] 6; | [XY]WO0172341 (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.25,l.3-9; p.38,l.19 to p.39, l.12; p.69,l.1 to p.70,l.23; Examples 3,5,7,10,14, p.194-197; claims 12,13,31,32,42 * [Y] 6; | [XY]WO0039319 (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.38,l.13 to p.39,l.24; Examples 1,3, claims 13,45,46; Figure 28 * [Y] 6; | [XY]WO2005112541 (PROYECTO BIOMEDICINA CIMA SL [ES], et al) [X] 1-5,7-15 * the whole document, in particular p.10,l.25 to p.11,l.4; p.18,l.14 to p.19,l.2; p.26,l.13 to p.27,l.29; Figures 2,7; SEQ ID NOs: 7,9,11, claims 8,24,25 * [Y] 6; | [XY]WO9839465 (CALYDON INC [US], et al) [X] 1-3,5,7-15 * the whole document, in particular p.21,l.17-32; SEQ ID NO: 2 * [Y] 6; | [A]US2006068370 (WANG MEI-CHIH [TW], et al) [A] 1-15; | [X] - "Homo sapiens BAC clone RP11-580P21 from 4, complete sequence.", EMBL, (20020129), Database accession no. AC108157, URL: EBI, XP002421520 [X] 4 * see sequence, in particular 97911-102095 * | [Y] - MANDELL ROBERT B ET AL, "Radioisotope concentrator gene therapy using the sodium/iodide symporter gene", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19990201), vol. 59, no. 3, ISSN 0008-5472, pages 661 - 668, XP002134372 [Y] 6 * the whole document * | [Y] - FILETTI S ET AL, "Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism", EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, (199911), vol. 141, no. 5, ISSN 0804-4643, pages 443 - 457, XP002258682 [Y] 6 * the whole document * DOI: http://dx.doi.org/10.1530/eje.0.1410443 | [Y] - SPITZWEG C ET AL, "Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20001115), vol. 60, no. 22, ISSN 0008-5472, pages 6526 - 6530, XP002258676 [Y] 6 * the whole document * | [A] - WATANABE K ET AL, "CELL-SPECIFIC ENHANCER ACTIVITY IN A FAR UPSTREAM REGION OF THE HUMAN ALPHA FETOPROTEIN GENE", JOURNAL OF BIOLOGICAL CHEMISTRY, (1987), vol. 262, no. 10, ISSN 0021-9258, pages 4812 - 4818, XP002067679 [A] 1-15 | [A] - AKIO IDO ET AL, "GENE THERAPY FOR HEPATOMA CELLS USING A RETROVIRUS VECTOR CARRYING HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE UNDER THE CONTROL OF HUMAN ALPHA-FETOPROTEIN GENE PROMOTER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19950715), vol. 55, ISSN 0008-5472, pages 3105 - 3109, XP002123061 [A] 1-15 | [A] - "Homo sapiens AFP gene for alpha-fetoprotein, promoter region.", EMBL, (20010306), Database accession no. AB053572, URL: EBI, XP002421521 [A] 1-15 | by applicant | WO2004112824 | WO2004011824 | WO9845443 | US2005261232 | US5093246 | US5116742 | US2003105043 | US2003195164 | US2005261249 | US2005113328 | US2005026860 | US2005026857 | US2004043950 | US2004009156 | US2003158130 | US2003036521 | WO9728175 | WO9412650 | WO9412649 | WO9412629 | US5922576 | WO9402595 | WO9323569 | WO9905094 | WO9904819 | WO9610391 | WO9610390 | WO9610392 | - HANAHAN D.; WEINBERG R. A., CELL, (2000), vol. 100, pages 57 - 70 | - SCHALLY; NAGY, EUROP J ENDOCTINOL, (1999), vol. 141, page 1 | - WHITNEY ET AL., CANCER, (1995), vol. 76, page 20 | - LASKE ET AL., NEUROSURG, (1997), vol. 41, page 1039 | - VOSE ET AL., LEUKEMIA & LYMPHOMA, (2000), vol. 38, page 91 | - MURASZKO ET AL., CANCER RES, (1983), vol. 53, page 3752 | - FAULK ET AL., MOL BIOTHERAPY, (1990), vol. 2, page 57 | - BERCZI ET AL., ARCH BIOCHEM BIOPHY, (1993), vol. 300, page 356 | - BEYER ET AL., J MED CHEM, (1998), vol. 41, page 2701 | - KRATZ ET AL., J PHARM SCI, (1998), vol. 87, page 338 | - BINLEY K. ET AL., GENE THERAPY, (1999), vol. 6, pages 1721 - 1727 | - HEISE C. ET AL., NATURE MEDICINE, (1997), vol. 3, pages 639 - 645 | - PARR M. J. ET AL., NATURE MEDICINE, (1997), vol. 3, pages 1145 - 1149 | - BENIHOUD K. ET AL., CURR. OPIN. BIOTECHNOL., (1999), vol. 10, pages 440 - 447 | - SMITH; WATERMAN, ADD. APL. MATH., (1981), vol. 2, page 482 | - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443 | - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI., (1988), vol. 85, page 2444 | - WATANABE ET AL., J. BIOL., CHEM., (1987), vol. 282, no. 10, pages 4812 - 4818 | - LOVANNA ET AL., J BIOL CHEM, (1991), vol. 266, pages 24664 - 24669 | - DUSETTI ET AL., J BIOL CHEM, (1995), vol. 270, no. 38, pages 22417 - 22421 | - SARKAR ET AL., BIOTECHNIQUES SUPPL, (2002), pages 30 - 39 | - FISHER ET AL., CANCER BIOL THER, (2003), vol. 2, pages 23 - 37 | - ANDERSON ET AL., CURR OPIN PHARMACOL, (2004), vol. 4, no. 4, pages 314 - 320 | - YOSHIDA ET AL., CANCER SCI, (2004), vol. 95, no. 11, pages 858 - 865 | - HAUPT ET AL., CELL CYCLE, (2004), vol. 3, no. 7, pages 912 - 916 | - CHAN ET AL., CLIN EXP PHARMACOL PHYSIOL, (2004), vol. 31, no. 3, pages 119 - 128 | - SANSAL ET AL., J CLIN ONCOL, (2004), vol. 22, no. 14, pages 2954 - 63 | - GOWARDHAN ET AL., PROSTATE, (2004), vol. 61, no. 1, pages 50 - 59 | - LIU ET AL., CANCER GENE THER, (2004), vol. 11, no. 11, pages 748 - 756 | - QUI ET AL., HEPATOBILIARY PANCREAT DIS INT, (2004), vol. 3, no. 4, pages 552 - 557 | - SARKAR ET AL., PHARMACOL THER, (2004), vol. 104, no. 2, pages 101 - 115 | - LEIBERMANN ET AL., LEUKEMIA, (2002), vol. 16, no. 4, pages 527 - 41 | - MITROFANOVA ET AL., CLIN CANCER RES, (2004), vol. 10, no. 20, pages 6969 - 6976 | - J. GOMEZ-NAVARRO ET AL., "Gene therapy for cancer", EUROPEAN JOURNAL OF CANCER, (1999), vol. 35, doi:doi:10.1016/S0959-8049(99)00061-1, pages 867 - 885, XP002959624 DOI: http://dx.doi.org/10.1016/S0959-8049(99)00061-1 | - J. A. ROTH ET AL., "Gene therapy for cancer: what have we done and where are we going?", JOURNAL OF THE NATIONAL CANCER INSTITUTE, (1997), vol. 89, no. 1, pages 21 - 39 | - D. KLATZMANN ET AL., "A Phase 1/11 dose-escalation study of herpes simplex virus type 1 thymidine kinase ''suicide'' gene therapy for recurrent metastatic melanoma", HUMAN GENE THERAPY, (1998), vol. 9, pages 2585 - 2894 | - J. R. HERMAN ET AL., "In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial", HUMAN GENE THERAPY, (1999), vol. 10, doi:doi:10.1089/10430349950018229, pages 1239 - 1249, XP000983940 DOI: http://dx.doi.org/10.1089/10430349950018229 | - BORKHARDT, A., "Blocking oncogenes in malignant cells by RNA interference : New hope for a highly specific cancer treatment?", CANCER CELL, (2002), vol. 2, no. 3, doi:doi:10.1016/S1535-6108(02)00129-0, pages 167 - 8, XP009006463 DOI: http://dx.doi.org/10.1016/S1535-6108(02)00129-0 | - WILDA, M. ET AL., "Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi", ONCOGENE, (2002), vol. 21, no. 37, doi:doi:10.1038/sj.onc.1205653, pages 5716 - 24, XP009009806 DOI: http://dx.doi.org/10.1038/sj.onc.1205653 | - BRUMMELKAMP, T. R.; R. BERNARDS; R. AGAMI, "Stable suppression of tumourigenicity by virus-mediated RNA interference", CANCER CELL, (2002), vol. 2, no. 3, doi:doi:10.1016/S1535-6108(02)00122-8, pages 243 - 7, XP009006464 DOI: http://dx.doi.org/10.1016/S1535-6108(02)00122-8 | - P. D. ZAMORE, SCIENCE, (2002), vol. 296, page 1265 | - HAMMOND ET AL., NAT. REV. GENET, (2001), vol. 2, pages 110 - 119 | - NORRIS ET AL., "Design and testing of ribozymes for cancer gene therapy", ADV. EXP MED. BIOL., (2000), vol. 465, pages 293 - 301 | - HASELHOFF ET AL., NATURE, (1988), vol. 334, pages 585 - 591 | - FAIVRE ET AL., CANCER RESEARCH, (2004), vol. 64, pages 8045 - 8051 | - HARRINGTON ET AL., NAT GENET, (1997), vol. 15, page 345 | - SMITH, ANNU. REV. MICROBIOL., (1995), vol. 49, page 807 | - ROSENFELD ET AL., CELL, (1992), vol. 68, page 143 | - LOGAN; SHENK, PROC. NATL. ACAD. SCI., (1984), vol. 81, page 3655 | - MILLER ET AL., MOL. CELL. BIOL., (1990), vol. 10, page 4239 | - KOLBERG, J. NIH RES., (1992), vol. 4, page 43 | - CORNETTA ET AL., HUM. GENE THER., (1991), vol. 2, page 215 | - TONG-CHUAN ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 2590 - 2514 | - AKHTAR ET AL., TRENDS CELL BIO., (1992), vol. 2, page 139 | - GOLD, NEUROSCIENCE, (1997), vol. 76, pages 1153 - 1158 | - HO ET AL., CURR. OPIN. MOL. THER., (1999), vol. 1, pages 336 - 343 | - GROOTHUIS ET AL., J NEUROVIROL., (1997), vol. 3, pages 387 - 400 | - JOLLIET-RIANT; TILLEMENT, FUNDAM. CLIN. PHARMACOL., (1999), vol. 13, pages 16 - 26 | - EMERICH, DF ET AL., CELL TRANSPLANT, (1999), vol. 8, pages 47 - 58 | - PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (1999), vol. 23, pages 941 - 949 | - BOADO ET AL., J. PHARM. SCI., (1998), vol. 87, pages 1308 - 1315 | - TYLER ET AL., FEBS LETT., (1999), vol. 421, pages 280 - 284 | - PARDRIDGE ET AL., PNAS USA, (1995), vol. 92, pages 5592 - 5596 | - BOADO, ADV. DRUG DELIVERY REV., (1995), vol. 15, pages 73 - 107 | - ALDRIAN-HERRADA ET AL., NUCLEIC ACIDS RES., (1998), vol. 26, pages 4910 - 4916 | - TYLER ET AL., PNAS USA, (1999), vol. 96, pages 7053 - 7058 | - LASIC ET AL., CHEM. REV., (1995), vol. 95, pages 2601 - 2627 | - ISHIWATA ET AL., CHEM. PHARM. BULL., (1995), vol. 43, pages 1005 - 1011 | - LASIC ET AL., SCIENCE, (1995), vol. 267, pages 1275 - 1276 | - OKU ET AL., BIOCHIM. BIOPHYS. ACTA, (1995), vol. 1238, pages 86 - 90 | - LIU ET AL., J. BIOL. CHEM., (1995), vol. 42, pages 24864 - 24870 | - HE ET AL., P.N.A.S, (1998), vol. 95, pages 2509 - 14 | WO2001US13000 |